The group had 11 patients with renal cell carcinoma who were diagnosed between the years of 1972 and 2004. The charts were retrospectively reviewed. Clinical features, histopathology, treatment regimens and outcomes of the patients were evaluated.

The group found that the male to female ratio was 3 to 8. The median age was 10 years. Three patients had stage I disease, 1 patient had stage II, 3 patients in IIIb, and 4 pateints in stage IV. Five of 7 patients that fell within stage II-IV received an actinomycin D-based regimen, one received a cisplatin-based regimen, and the other was given 5-fluorouracil in combination with interferon-alpha. One of the patients who was given actinomycin D also received interferon-alpha as well.

All of the stage I patients were alive without disease. Three patients with stage IIIb, stage IV and stage II disease are alive without disease, 8, 14, and 26 years after their diagnosis, respectively. The other stage IV and stage IIIb patients died of their disease. All of their patients had nephroureteroctomies.

The group concluded that nephroureteroectomy is the main treatment modality and it is sufficient for stage I patients without any further therapy. For patients with stage II-IV renal cell carcinoma, interferon-alpha and/or actinomycin D-based chemotherapy should probably be the treatment of choice.

Varan A, Akyuz C, Sari N, Buyukpamukcu N, Caglar M, Buyukpamukcu M.

Nephron Clinical Practice 105(2): 58-61, 2007.

Written by Pasquale Casale, MD, a Contributing Editor with UroToday.

Please log-in or register in order to submit comments.

Powered by AkoComment!